Potential for cytokine and product manipulation to improve the results of autologous stem cell transplantation for rheumatoid arthritis

Basit Öğe Kaydı
dc.authoridTalmadge, James/0000-0002-6328-6056
dc.authoridTalmadge, James Edward/0000-0002-6328-6056
dc.authoridTalmadge, James/0000-0002-6328-6056
dc.authoridG. Ageitos, Ana/0000-0002-7191-4534
dc.authorwosidTalmadge, James/AAX-6449-2020
dc.authorwosidTalmadge, James Edward/A-5916-2008
dc.authorwosidTalmadge, James/AAF-7242-2020
dc.contributor.authorTalmadge, JE
dc.contributor.authorSingh, R
dc.contributor.authorIno, K
dc.contributor.authorAgeitos, A
dc.contributor.authorBuyukberber, S
dc.date.accessioned2024-08-04T21:00:11Z
dc.date.available2024-08-04T21:00:11Z
dc.date.issued2001
dc.departmentİnönü Üniversitesien_US
dc.descriptionWorkshop on the Role of Hematopoietic Stem Cell Transplantation for Rheumatoid Arthritis -- MAR 26, 2000 -- ANAHEIM, CAen_US
dc.description.abstractThe eradication of autoreactive T cells by high dose therapy and stein cell transplantation and the resultant alterations in the immunologic network, thymic reeducation, and peripheral tolerance provide treatment mechanisms for autoimmune and inflammatory diseases. One outcome of autologous stein cell transplantation is a significant decrease in the CD4:CD8 ratio due to a loss in CD4+ cells and a depression in T cell function. Mechanistically, the loss of T cell function is associated with an increased frequency of circulating monocytes, their expression of Fas ligand (FasL). and it high frequency of apoptotic CD4+ T cells. This suggests that activated Fas+ CD4+ lymphocytes interact with FasL+ monocytes, resulting in apoptosis, preferential deletion of CD4+ T cells, an inversion in the CD4:CD8 ratio, and depressed T cell function. These observations suggest the potential for immune regulation using stem cell manipulation or posttransplant cytokine administration its therapeutic strategies for autoimmune/inflammatory diseases.en_US
dc.description.sponsorshipInt Bone Marrow Transplant Registry,Autologous Blood and Marrow Transplant Registry,Amgen,Aventis Pharmaceut,Nexell Therapeut Inc,Pharmacia & Upjohn,Sangstat Med Corp,Supergenen_US
dc.description.sponsorshipNCI NIH HHS [R01-CA61593] Funding Source: Medlineen_US
dc.identifier.endpage38en_US
dc.identifier.issn0315-162X
dc.identifier.issn1499-2752
dc.identifier.pmid11642502en_US
dc.identifier.startpage32en_US
dc.identifier.urihttps://hdl.handle.net/11616/103876
dc.identifier.volume28en_US
dc.identifier.wosWOS:000171482400009en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJ Rheumatol Publ Coen_US
dc.relation.ispartofJournal of Rheumatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectperipheral toleranceen_US
dc.subjectrheumatoid arthritisen_US
dc.subjectstem cell transplantationen_US
dc.titlePotential for cytokine and product manipulation to improve the results of autologous stem cell transplantation for rheumatoid arthritisen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu